Marco Boorsma PhD
General Partner
Orbis’ platform is the first to systematically explore the macrocycle chemical space using a unique combination of high-throughput chemical synthesis and large-scale assaying, supported by machine learning
Orbis Medicines is a leader in oral macrocycle drug discovery. Macrocycles are a large and diverse family of compounds with highly desirable therapeutic properties defined by the presence of a cyclic structure.
The company's portfolio of next-generation macrocycle drugs called ‘nCycles’ are systematically designed by Orbis’ nGen platform to be orally bioavailable and membrane permeable, solving decades-long challenges in macrocycle drug design.
Industry
Biotech
Status
Current
Location
Denmark
It has been a true pleasure to work with the broader Forbion team – from seeding the company with a shared vision of disrupting the biologics market with a novel oral macrocycle modality the Forbion team has provided valuable market insights and network facilitating raising one of the largest Series A rounds in Europe in 2025.Morten Graugaard
CEO of Orbis Medicines
